Melphalan flufenamide Disease Interactions
There are 3 disease interactions with melphalan flufenamide.
Antineoplastics (applies to melphalan flufenamide) infections
Major Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral
Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression. The use of these drugs may be contraindicated in patients with known infectious diseases. All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy. Close clinical monitoring of hematopoietic function is recommended.
References
- "Product Information. Methotrexate (methotrexate)." Lederle Laboratories PROD (2002):
- "Product Information. Platinol (cisplatin)." Bristol-Myers Squibb PROD (2001):
- "Product Information. Vepesid (etoposide)." Bristol-Myers Squibb PROD (2001):
- "Product Information. Novantrone (mitoxantrone)." Immunex Corporation PROD (2001):
- "Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb PROD (2001):
- "Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb PROD (2001):
- "Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation) PROD (2001):
- "Product Information. Fludara (fludarabine)." Berlex Laboratories PROD (2001):
- "Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn PROD (2001):
- "Product Information. Matulane (procarbazine)." Roche Laboratories PROD (2001):
- "Product Information. DTIC-Dome (dacarbazine)." Bayer PROD (2001):
- "Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn PROD (2001):
- "Product Information. Leustatin (cladribine)." Ortho Biotech Inc PROD (2001):
- "Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company PROD (2001):
- "Product Information. Hycamtin (topotecan)." SmithKline Beecham PROD (2001):
- "Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer PROD (2001):
- "Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb PROD (2001):
- "Product Information. Nipent (pentostatin)." Hospira Inc PROD (2001):
- "Product Information. Tabloid (thioguanine)." Prasco Laboratories PROD (2001):
- "Product Information. Xeloda (capecitabine)." Roche Laboratories PROD (2001):
- "Product Information. Alkeran (melphalan)." Glaxo Wellcome (2022):
- "Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome PROD (2001):
- "Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.
- "Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc PROD (2001):
- "Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn PROD (2001):
- "Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation PROD (2001):
- "Product Information. Jevtana (cabazitaxel)." sanofi-aventis (2010):
- "Product Information. Halaven (eribulin)." Eisai Inc (2010):
- "Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc. (2021):
Melphalan flufenamide (applies to melphalan flufenamide) bone marrow suppression
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Bone Marrow Depression/Low Blood Counts
Bone marrow suppression is the most significant toxicity associated with melphalan flufenamide in most patients. It is recommended to perform the following tests at the start of therapy and prior to each subsequent dose of melphalan flufenamide: platelet count, hemoglobin, white blood cell count, and differential. Thrombocytopenia and/or neutropenia are indications to withhold further therapy until the blood counts have sufficiently recovered. Monitor blood counts frequently to determine optimal dosage and to avoid toxicity. Consider prophylactic therapy such as leukocyte growth factor as clinically appropriate. Dose adjustment on the basis of blood counts at the nadir and day of treatment should be considered.
References
- "Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc. (2021):
Melphalan flufenamide (applies to melphalan flufenamide) renal dysfunction
Moderate Potential Hazard, Moderate plausibility.
No dose adjustment of melphalan flufenamide is recommended in patients with creatinine clearance (CrCl) 45 to 89 mL/min. Care should be exercised when using this agent in patients with CrCl 15 to 44 mL/min as the safety and efficacy has not been studied in these patients.
References
- "Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc. (2021):
Melphalan flufenamide drug interactions
There are 253 drug interactions with melphalan flufenamide.
More about melphalan flufenamide
- melphalan flufenamide consumer information
- Check interactions
- Compare alternatives
- Latest FDA alerts (1)
- Side effects
- Dosage information
- During pregnancy
- Drug class: alkylating agents
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.